2023.03.20
I-Mab to Report Full Year 2022 Financial Results and Provide Corporate Update on March 31, 2023
The Company announced date of reporting financial results for year 2022.
2023.03.20
The Company announced date of reporting financial results for year 2022.
2023.03.13
I-Mab today issued a statement on the recent developments of the SVB.
2023.03.07
I-Mab has been granted “A” rating by Morgan Stanley Capital International ESG.
2022.11.03
Two poster presentations featuring preclinical and translational research data of lemzoparlimab will be presented at the 2022 ASH Annual Meeting.
2022.10.05
I-Mab will present new preclinical data of its core assets lemzoparlimab and uliledlimab at the 37th SITC Annual Meeting.
2022.09.13
I-Mab has successfully completed an EoP2 meeting with the CDE of China’s NMPA, and has obtained approval to initiate a Phase 3 registrational trial evaluating lemzoparlimab in combination with AZA for the first-line treatment of patients with newly diagnosed HR-MDS.
2022.09.10
I-Mab today announces encouraging data from its Phase 2 clinical trial of lemzoparlimab in combination with azacitidine in patients with newly diagnosed HR-MDS.
2022.09.06
I-Mab today announced that the results from its Phase 2 clinical study of lemzoparlimab in combination with azacitidine in patients with HR-MDS will be featured in a proffered paper presentation at the upcoming ESMO Congress 2022.
2022.08.30
I-Mab today announced financial results for the six months ended June 30, 2022, and provided key business updates.
2022.08.23
I-Mab today announced that it plans to implement share repurchases pursuant to the share repurchase program previously authorized by its Board of Directors.